Novo Nordisk's oral weight loss pill, Amycretin, demonstrated 10.4-13.4% body weight loss in phase 1 trials, outperforming placebo.

Novo Nordisk's oral weight loss pill, Amycretin, has shown encouraging results in early trials. In a phase 1 study, participants lost 10.4% of their body weight at the lowest dose and over 13% at a higher dose over 12 weeks, compared to just 1% for those on a placebo. Amycretin targets GLP-1 and amylin hormone receptors, similar to existing injectable weight loss drugs.

September 25, 2024
3 Articles